EPCAM and type 1 diabetes mellitus: Some examples, including ADA for adult T-cell leukemia (ATL), CD3D for T1DM and EPCAM for hepatitis C (HC), are known target–disease associations, indicating that our proposed method can accurately predict known therapeutic indications.